Cell Division and the Cell Cycle

Introduction to the Cell Cycle

The cell cycle is the ordered sequence of events by which a cell duplicates its contents and divides into two daughter cells. Accurate cell cycle progression is essential for development, tissue homeostasis, and reproduction. The cycle is divided into interphase (G1, S, G2) and mitotic (M) phases. S phase replicates the entire genome; M phase segregates duplicated chromosomes; G1 and G2 gaps allow growth and preparation. Cells that stop dividing exit to quiescence (G0). Dysregulation of cell cycle control is a hallmark of cancer—most oncogenes and tumour suppressors act in cell cycle regulatory pathways.

Cell cycle progression is driven by cyclin-dependent kinases (CDKs) activated by regulatory cyclin subunits whose abundance fluctuates through the cycle. Different cyclin-CDK complexes (cyclin D-CDK4/6 in G1, cyclin E-CDK2 at G1/S, cyclin A-CDK2 in S, cyclin B-CDK1 in G2/M) phosphorylate substrates driving each transition. Ubiquitin-mediated degradation of cyclins by the anaphase-promoting complex (APC/C) and SCF E3 ligases creates irreversibility—cycle transitions are unidirectional bistable switches preventing backwards progression.

Cell Cycle Checkpoints

G1/S and DNA Damage Checkpoints

The G1/S checkpoint prevents replication of damaged DNA. The retinoblastoma protein (Rb) binds E2F transcription factors, repressing S phase genes. Cyclin D-CDK4/6 and cyclin E-CDK2 hyperphosphorylate Rb, releasing E2F to activate S phase entry. The tumour suppressor p53 is activated by DNA damage (via ATM/ATR kinases phosphorylating and stabilising p53); p53 transcribes p21 (CDKN1A), which inhibits cyclin-CDK complexes halting cell cycle progression to allow repair. If damage is irreparable, p53 induces apoptosis. TP53 is the most commonly mutated gene in human cancers—its loss removes the critical damage checkpoint.

Spindle Assembly Checkpoint

The spindle assembly checkpoint (SAC) prevents anaphase until all kinetochores (chromosomal centromere attachment points) are properly attached to spindle microtubules under tension. Unattached kinetochores catalytically produce mitotic checkpoint complex (MCC) which inhibits the APC/C-Cdc20 complex that would trigger anaphase. A single unattached kinetochore can delay mitosis in the entire cell. Kinetochore-microtubule error correction by Aurora B kinase ensures amphitelic (correct) attachments; tension stabilises attachments while Aurora B destabilises incorrect ones. SAC failure causes chromosomal instability—aneuploidy contributing to cancer and developmental abnormalities.

Mitosis and Cytokinesis

Chromosome Segregation

In mitosis, prophase chromosomes condense; nuclear envelope breaks down; spindle assembles from centrosomes using dynamic microtubules; chromosomes attach to spindle at kinetochores; chromosomes align at the metaphase plate; sister chromatids separate at anaphase when APC/C-Cdc20 ubiquitinates securin (releasing separase that cleaves cohesin) and cyclin B (inactivating CDK1); chromatids move to poles. Cytokinesis divides cytoplasm through actomyosin ring contraction. Errors in segregation cause missegregation—one daughter cell gaining an extra chromosome (trisomy) and the other losing one (monosomy)—a mechanism of cancer chromosomal instability.

Meiosis and Genetic Recombination

Meiosis generates haploid gametes through two sequential divisions: meiosis I separates homologous chromosomes (including DNA crossovers/recombination creating genetic shuffling); meiosis II separates sister chromatids like mitosis. Crossovers in meiosis I are required for proper chromosome segregation—without crossovers, homologues fail to orient correctly causing non-disjunction. Genome-wide recombination generates enormous genetic diversity in offspring. Errors in meiotic non-disjunction cause trisomies (Down syndrome—extra chromosome 21; Turner syndrome—single X; Klinefelter—XXY) whose frequency increases with maternal age due to prolonged dictyotene arrest of oocytes.

Cell Cycle Dysregulation in Cancer

Cancer results from accumulated somatic mutations disabling cell cycle controls. Oncogenes (gain-of-function mutations): RAS mutations activate proliferative MAPK signalling; MYC amplification drives transcription of cell cycle genes; cyclin D amplification or CDK4/6 overactivation bypasses G1 checkpoint. Tumour suppressors (loss-of-function): Rb loss removes E2F inhibition; p53 loss removes damage checkpoints; p16(INK4a)/CDKN2A loss removes CDK4/6 inhibition. Modern targeted therapies exploit these vulnerabilities—CDK4/6 inhibitors (palbociclib, ribociclib) in Rb-competent breast cancer block proliferative signalling precisely where tumours are addicted.

Examples and Applications

Example 1: CDK4/6 Inhibitors in Breast Cancer

CDK4/6 inhibitors block cyclin D-CDK4/6 phosphorylation of Rb, maintaining E2F repression preventing S phase entry. In ER+/HER2- breast cancers dependent on cyclin D-CDK4/6 signalling, palbociclib combined with endocrine therapy doubled progression-free survival compared to endocrine therapy alone in registration trials. Three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are approved, transforming treatment of the most common breast cancer subtype. Mechanisms of resistance (Rb loss, CDK6 upregulation) are targets for next-generation approaches.

Example 2: Taxanes and Spindle Poison Chemotherapy

Taxanes (paclitaxel, docetaxel) stabilise polymerised microtubules preventing their dynamic instability needed for chromosome capture and segregation. Spindle microtubules fail to shorten pulling chromosomes to poles; the spindle assembly checkpoint arrests cells in mitosis; prolonged mitotic arrest triggers apoptosis. Taxanes are highly effective in breast, ovarian, and lung cancers. Resistance includes overexpression of MDR efflux pump, tubulin mutations, and expression of alternative tubulin isoforms binding taxanes less well. Understanding resistance mechanisms guides next-generation approaches including nanoparticle drug delivery targeting tumour vasculature.

Example 3: p53 as Guardian of the Genome

p53 transcription factor is activated by DNA damage, oncogene activation, hypoxia, and ribonucleotide depletion via ATM/ATR-Chk1/2 kinase cascades. p53 transcribes target genes inducing cell cycle arrest (p21), DNA repair (GADD45), apoptosis (PUMA, NOXA, BAX), or senescence (p21, PAI-1). TP53 is mutated in over 50% of human cancers; hotspot mutations often create dominant-negative or gain-of-function p53 proteins in addition to losing normal function. Restoring p53 activity in tumours through MDM2 inhibitors (which normally target p53 for degradation) is a therapeutic strategy in TP53 wild-type tumours with MDM2 amplification.

Example 4: Telomere Shortening and Cell Senescence

Telomeres—repetitive DNA caps protecting chromosome ends—shorten with each replication cycle because DNA polymerase cannot fully replicate the 3' end (end-replication problem). Critically short telomeres activate DNA damage response, causing irreversible cell cycle arrest (replicative senescence). This limits normal cells to Hayflick's limit (~50 doublings). Cancer cells reactivate telomerase (TERT) or use alternative lengthening of telomeres (ALT) to maintain telomere length indefinitely. Telomerase is an attractive cancer target; telomere biology connects ageing, cellular senescence, and cancer in a single molecular framework.

Example 5: Aneuploidy in Early Embryos

Preimplantation genetic testing (PGT-A) of IVF embryos reveals that 40-60% of human blastocysts have numerical chromosomal abnormalities (aneuploidy). Aneuploid embryos mostly fail to implant or miscarry early; rarely, trisomies 21, 18, 13, and sex chromosome aneuploidies survive to birth. Aneuploidy rate increases sharply with maternal age due to age-related cohesin deterioration in oocytes arrested in meiosis I for decades. PGT-A selects euploid embryos for transfer, improving implantation rates particularly in older patients and those with recurrent miscarriage.

Example 6: Cyclin D and Mantle Cell Lymphoma

Mantle cell lymphoma carries the t(11;14) translocation placing cyclin D1 under the immunoglobulin heavy chain promoter, causing constitutive overexpression. Cyclin D1-CDK4/6 hyperphosphorylates Rb bypassing G1 arrest, driving uncontrolled proliferation. Cyclin D1 overexpression by IHC is thus diagnostic for mantle cell lymphoma. CDK4/6 inhibitors are being evaluated in mantle cell lymphoma; BTK inhibitors (ibrutinib) targeting BCR signalling are approved. The translocation discovery illustrates how understanding oncogene mechanisms directly enables molecular diagnosis and targeted therapy development.

Example 7: G2/M Checkpoint in Radiation Therapy

Radiation therapy kills cancer cells through DNA double strand breaks (DSBs). G2/M checkpoint activation arrests cells before mitosis to repair DSBs; cells that cannot repair die in mitosis. Normal cells tolerate radiation better because they have intact G1 checkpoint (p53-p21) and G2/M checkpoint providing two opportunities to repair damage. Cancer cells with p53 mutations lose G1 checkpoint, making them more dependent on G2/M checkpoint—which CHK1 inhibitors target. Combining CHK1 inhibitors with radiation to abrogate G2/M checkpoint selectively sensitises p53-mutant cancer cells, an example of synthetic lethality-inspired radiation sensitisation.

Example 8: AURKA and Chromosome Instability

Aurora A kinase (AURKA) regulates mitotic spindle assembly, centrosome maturation, and chromosome segregation accuracy. AURKA overexpression—common in breast, ovarian, and colorectal cancers—causes premature mitotic entry, spindle defects, and chromosomal instability. AURKA inhibitor (alisertib) entered clinical trials; while toxicity from normal cell disruption limited single-agent activity, combinations with chemotherapy show promise. Understanding Aurora kinase biology reveals how seemingly subtle cell cycle changes drive the chromosomal instability that fuels cancer genetic evolution and therapy resistance.

Try it live

Everything above runs in your browser — open Cell Cycle Clock Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.